71 related articles for article (PubMed ID: 30369183)
1. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
[No Abstract] [Full Text] [Related]
2. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
[TBL] [Abstract][Full Text] [Related]
3. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
4. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
Ren Y; Liu F; Chen X; Zhang X; Zhao B; Wan Y; Lan Y; Li X; Yang W; Zhu X; Guo Y
Ann Hematol; 2024 Apr; 103(4):1345-1351. PubMed ID: 38316642
[TBL] [Abstract][Full Text] [Related]
5. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Gao XN; Su YF; Li MY; Jing Y; Wang J; Xu L; Zhang LL; Wang A; Wang YZ; Zheng X; Li YF; Liu DH
Cancer Immunol Immunother; 2023 Aug; 72(8):2769-2782. PubMed ID: 37166484
[TBL] [Abstract][Full Text] [Related]
6. [Survival and Prognosis of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome].
Shang LM; Chen HJ; Liu Y; Cao Y; Li F; Guo YT; Dong WM; Lin Y; Gu WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):347-354. PubMed ID: 38660835
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Becker PS; Kantarjian HM; Appelbaum FR; Petersdorf SH; Storer B; Pierce S; Shan J; Hendrie PC; Pagel JM; Shustov AR; Stirewalt DL; Faderl S; Harrington E; Estey EH
Br J Haematol; 2011 Oct; 155(2):182-9. PubMed ID: 21848522
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine.
Huang S; Chen P; Wang L; Xu L; Wang N; Li F; Dou L; Liu D
Cancer Pathog Ther; 2024 Apr; 2(2):112-120. PubMed ID: 38601484
[TBL] [Abstract][Full Text] [Related]
9. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract][Full Text] [Related]
10. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.
Rosenberg PS; Alter BP; Bolyard AA; Bonilla MA; Boxer LA; Cham B; Fier C; Freedman M; Kannourakis G; Kinsey S; Schwinzer B; Zeidler C; Welte K; Dale DC;
Blood; 2006 Jun; 107(12):4628-35. PubMed ID: 16497969
[TBL] [Abstract][Full Text] [Related]
11. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults.
Yoo KH; Cho J; Han B; Kim SH; Shin DY; Hong J; Kim H; Kim HJ; Zang DY; Yoon SS; Jin JY; Lee JH; Hong DS; Park SK
PLoS One; 2020; 15(8):e0235503. PubMed ID: 32760083
[TBL] [Abstract][Full Text] [Related]
13. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Penter L; Liu Y; Wolff JO; Yang L; Taing L; Jhaveri A; Southard J; Patel M; Cullen NM; Pfaff KL; Cieri N; Oliveira G; Kim-Schulze S; Ranasinghe S; Leonard R; Robertson T; Morgan EA; Chen HX; Song MH; Thurin M; Li S; Rodig SJ; Cibulskis C; Gabriel S; Bachireddy P; Ritz J; Streicher H; Neuberg DS; Hodi FS; Davids MS; Gnjatic S; Livak KJ; Altreuter J; Michor F; Soiffer RJ; Garcia JS; Wu CJ
Blood; 2023 Apr; 141(15):1817-1830. PubMed ID: 36706355
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.
Huang HH; Chen CM; Wang CY; Hsu WW; Chen HM; Ko BS; Hsiao FY
PLoS One; 2022; 17(1):e0261871. PubMed ID: 35061709
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Najima Y; Maeda T; Kamiyama Y; Nakao S; Ozaki Y; Nishio H; Tsuchihashi K; Ichihara E; Miumra Y; Endo M; Maruyama D; Yoshinami T; Susumu N; Takekuma M; Motohashi T; Ito M; Baba E; Ochi N; Kubo T; Uchino K; Kimura T; Tamura S; Nishimoto H; Kato Y; Sato A; Takano T; Yano S
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38755516
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.
Li Y; Mao X; Li M; Li L; Tong X; Huang L
Clin Epigenetics; 2024 Jan; 16(1):16. PubMed ID: 38254153
[TBL] [Abstract][Full Text] [Related]
18. Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
Kaplan HG; Calip GS; Malmgren JA
Oncologist; 2020 May; 25(5):391-397. PubMed ID: 32073195
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
Shi H; Yang F; Cao M; Xu T; Zheng P; Guo Y; Su G; Feng S; Li R; Liu R; Liu H; Ma L; Ke X; Hu K
Ann Hematol; 2024 Apr; ():. PubMed ID: 38662205
[TBL] [Abstract][Full Text] [Related]
20. Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience.
Bashir Y; Geelani S; Bashir N; Mir SA; Mushtaq M; Jan MA; Rasool J
South Asian J Cancer; 2015; 4(1):4-6. PubMed ID: 25839010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
